Generics & Biosimilars | Association for Accessible Medicines
AAM All Access Podcast - AAM CEO Dan Leonard convenes industry and policy experts to explore why the Inflation Reduction Act (f/k/a Build Back Better) reduces generic and biosimilar competition.
  • AAM All Access Podcast
    AAM Podcast: Build Back Better Hurts Patient Access to Generics and Biosimilars
    On the featured All Access Podcast, AAM CEO Dan Leonard convenes industry experts from Teva, Fresenius Kabi and policy expert Kurt Karst to explore why the Inflation Reduction Act (f/k/a Build Back Better) is still bad for America's patients.
  • Doesn't Add Up patient photo
    Take Action on Build Back Better Now!
    Congress is actively considering prescription drug reforms included in the Inflation Reduction Act (f/k/a Build Back Better) that would undermine access to the affordable FDA-approved generic and biosimilar medicines that millions of seniors rely on to manage their health. Send a message to your lawmaker now!
  • Markup Madness
    Who’s Profiting from Your Prescription?
    Unlike brand drugs where the manufacturer stands to profit the most, generic medicines are often exploited by middlemen that seize significant profits at the expense of patients and the companies that make the medicines.
  • GDUFA/BsUFA User Fees
    What Are GDUFA and BsUFA User Fees?
    Watch this this video to learn more about how the Generic Drug User Fee Amendments (GDUFA) and Biosimilar User Fee Act (BsUFA) help to get more generic and biosimilar medicines to patients more quickly.
    Watch Video
  • Ariel
    AAM Calls on FTC to Investigate PBM Business Practices
    “A distinct set of PBM business practices have resulted in higher prices and delayed access to generics and biosimilars for patients,” said AAM CEO Dan Leonard.
  • 2021 state savings map
    Generic Medicines Are Saving Your State Billions
    In 2020, generic and biosimilar medicines saved America's patients $338 billion. Find out how much your state saved with our interactive savings map.
  • Generics and Biosimilars are the Prescription for State Savings #Rx4StateSavings
    Prescription for State Savings
    State lawmakers can take meaningful action to lower brand prescription drug costs with the Prescription for State Savings. AAM outlines several solutions states could pursue.
  • AAM Voices of Access
    AAM Voices of Access
    Physicians, pharmacists, patients and caregivers across the country trust generics and biosimilars. Here are their stories, in their own words—along with perspectives from health care professionals and the AAM team.

Our Brands and Campaigns

Association for Accessible Medicines


Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.